Since the second half of the year, the repair rally in the innovative drug sector has been steadily advancing. A combination of favorable policy signals, accelerated corporate overseas expansion, and a strong earnings season is likely supporting the sector's recovery, suggesting its long-term allocation value is gaining recognition from the market.
As the only ETF currently tracking the Hang Seng Innovation Drug Index in the A-share market, the Huatai-PineBridge Hang Seng Innovation Drug ETF (520500) has attracted a total net inflow of 1.445 billion yuan this year. This has propelled its fund shares and asset scale to 2.21 billion units and 3.23 billion yuan, representing increases of 77% and 67% respectively from the start of the year, highlighting its strong liquidity advantage.
Overseas expansion is a key catalyst for the current rebound in the innovative drug sector, with domestic companies accelerating their global deployment. On August 10, the market saw three representative cross-border collaborations announced simultaneously, covering the three major models of overseas expansion: joint R&D, domestic commercialization of foreign drugs, and out-licensing of proprietary products. A leading innovative drug company partnered with Revolution Medicines to develop a joint oncology treatment plan, while also securing exclusive development and commercialization rights for four of the partner's clinical-stage candidates in parts of Asia. Another firm signed an agreement with Daiichi Sankyo to obtain the exclusive commercialization rights for Vyxeos in mainland China. A third local company partnered with Menarini to bring its proprietary GLP-1 innovative drug to the European market. The concentrated announcement of these three deals reflects the increasingly diverse roles domestic innovative drug companies are playing in global collaboration.
Earnings reports are also sending positive signals. During the current 2026 interim reporting season, a leading domestic CRO company reported its first-ever half-year net profit attributable to the parent company exceeding 10 billion yuan, reaching 11.08 billion yuan, while also raising its full-year performance guidance. On August 6, three core innovative drug companies released better-than-expected operational data, showing significant improvements in both revenue and clinical licensing income. The overall trend of these interim reports suggests the innovative drug industry may be gradually emerging from its early high-investment phase, with the profit generation capability of the industry chain continuing to strengthen.
Looking ahead, the deep integration of AI technology into drug development is expected to create a second growth curve for the innovative drug sector. The "Artificial Intelligence + Manufacturing" Special Action Implementation Opinion, released in early 2026, proposed building AI-driven platforms for new drug discovery and virtual screening. It also called for the creation of an AI-powered drug R&D platform, utilizing multimodal efficacy prediction models to accelerate target identification and lead compound discovery, reducing the drug development cycle and costs. Supported by a continuously improving policy environment, AI technology is poised to accelerate its penetration into the innovative drug R&D process, continually broadening the sector's long-term growth ceiling.
It is noted that the Huatai-PineBridge Hang Seng Innovation Drug ETF (520500), which closely tracks the Hang Seng Innovation Drug Index, invests in 40 leading Hong Kong-listed innovative drug companies through the QDII mechanism. It primarily focuses on mid-to-upstream innovative drug segments such as biopharmaceuticals, chemical pharmaceuticals, and active pharmaceutical ingredients, bringing together a group of R&D-driven enterprises with strong research capabilities and growth potential. This ETF, with its large scale, good liquidity, and support for on-exchange T+0 trading, could be a convenient tool for positioning for opportunities in Hong Kong-listed innovative drug stocks against the backdrop of business development (BD) deal monetization, profit inflection points, and policy support.
Huatai-PineBridge Hang Seng Innovation Drug ETF (520500) is managed by Huatai-PineBridge Fund Management, one of China's first ETF managers with over 19 years of experience in index investing. The company has provided investors with transparent, convenient, and low-cost index tools like the CSI 300 ETF Huatai-PineBridge (510300) and the A500 ETF Huatai-PineBridge (563360). As of the end of June 2026, the company's ETFs generated cumulative profits of over 180.6 billion yuan for holders in the past two years, making it one of only three public fund companies in the A-share market to have accumulated over 160 billion yuan in profits during that period. A MACD golden cross signal has formed; these stocks are performing well!